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________________________________________________________________________________ 
A recently proposed "ethynylogation" pharmacomodulation approach, first envisaged in the series 
of anticancer lipidic dialkynylcarbinols (DACs) H–C≡C–CH(OH)–C≡C–R at the levels of the H–
C⋮ and ⋮C–R bonds for R = n-C12H25, is completed here at the level of the (HO)C–H bond. The so-
devised mono-lipidic trialkynylcarbinol (TAC) target (HC≡C)2C(OH)–C≡CR and its bis-lipidic 
counterpart HC≡C–C(OH)(C≡CR)2 were synthesized in 4 steps with 33 % and 23 % overall yield, 
respectively. Their antitumor cytotoxicity has been evaluated towards HCT116 cells: while the 
latter doubly lipidic TAC is totally inactive (IC50 > 120 µM), the former DAC-ethynylogous TAC 
still exhibits a significant toxicity with an IC50 of 40 µM. 
________________________________________________________________________________ 




With the view to setting the title terms in a 
proper context, scholar emphasis is first given to 
the basic notion of structure-activity 
relationships (SARs), which correlate the 
presence of a generic chemical unit with 
particular biological/therapeutic effects [1]. The 
first-key SAR unit can be a global molecular 
skeleton that can be modified/ decorated by 
various second-key functional units (e.g. 
norsteroids, corticosteroids or macrolides, 
related to contraceptive, anti-inflammatory or 
antibiotic effects, respectively). On the other 
hand, the first-key SAR unit can be restricted to 
a local well-defined substructure, called a 
pharmacophore [2], that can be embedded in 
various second-key environments (e.g. beta-
lactams, benzodiazepines or arylpropionic acids 
related to antimicrobial, anxiolytic or analgesic 
effects, respectively). It is worth noting that 
SARs can be more or less specific: the number 
of identified antitumor pharmacophores is thus 
actually as large as the number of targetable 
biochemical pathways, and almost as large as 
the number of marketed anticancer drugs [3]. 
Classical optimization approaches around a 
given pharmacophore consist in sequential 
modifications of the local environment by 
isomerization (e.g. enantiomerization), 
reduction/oxidation (e.g. CH–OH → C=O), 
analogation (e. g. O→S, CH→N), C-H 
fluorination or general C-H substitution. 
Homologation (by CH2-insertion) and 
vinylogation (by –HC=CH- insertion) are also 
established pharmacomodulation approaches, 
within the pharmacophoric unit itself [4] or at 
its periphery. An alternative "ethynylogation" 
approach has been recently proposed [5,6]: it is 
based on the assumption that a third-key SAR 
criterion would be a distance constraint between 
the pharmacophore and any component of its 
surrounding, independently from any relative 
spatial orientation constraint between them (so 
regardless conformational effects).  
The ethynylogation approach has been first 
implemented in the series of synthetic lipidic 
dialkynylcarbinols (DACs) of general formula 
HC≡C–CH(OH)–C≡CR, inspired from natural 
lipidic alkenyl-alkynylcarbinols (AACs) (E)-
HC≡C–CH(OH)–CH=CHR extracted from 
marine sponges [7]. Beyond efforts aiming at the 
total synthesis of natural AACs [8], synthesis 
and biological evaluation of both simplified and 
modified congeners thereof allowed the 
identification of non-natural DACs as potent in 
vitro antitumor cytotoxic agents, in particular 
against the HCT116 cell-line [9]. Starting from 
the recently disclosed lead 1 (R = n-C12H25, IC50 
≈ 0.10 µM; Figure 1) [5,9a], the C5OH DAC unit 
itself, C≡C–C(OH)–C≡C, has been formally 
separated from either two components of its 
surrounding, the terminal acetylenic H and the 
lipidic chain R, by a distance of ca 2.4 ± 0.1 Å 
through the insertion of a C2 ethyndiyl unit. The 
corresponding independent ethynylogations thus 
defined the external and internal butadiynyl-
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alkynylcarbinols (BACs) 2 and 3, respectively, 
which were synthesized in either racemic or 90 
% ee-scalemic forms [5]. Compared to 1, while 
the external BAC 2 was found to display a 
decreased cytotoxicity (IC50 ≈ 10 µM for rac-2), 
the internal BAC 3 showed an enhancement 
thereof: IC50 = 0.12 µM for rac-3 and IC50 = 
0.04 µM for (S)-(+)-3, vs IC50 = 0.10 µM for 
(S)-(+)-1. A dramatic absolute configuration 
effect, previously observed for the DAC 1 [9a], 
was thus also evidenced for the BAC 3, with an 
eudismic ratio of ca one order of magnitude. 
 
 
Figure 1. Generalization of the ethynylogation approach 
in the lipidic DAC series. IC50 values correspond to 
cytotoxicity against HCT116 tumor cells (MTT tests) [5].   
 
The ethynylogation approach is hereafter 
implemented for the third surrounding 
component of the C5OH unit, namely the H 
atom of the secondary carbinol center of 1. The 
so-devised ethynylogous target is thus the 
trialkynylcarbinol (TAC) 4. Contrary to the 
DAC 1 and BAC 3, the TAC 4 is achiral, thus 
advantageously allowing disregard of 
asymmetric synthesis issues. 
Results and discussion 
The TAC target 4 was prepared in four steps 
from trimethylsilylacetylene via the previously 
known DAC 5 and corresponding diynone 6, 
obtained sequentially with 84 % and 82 % yield, 
respectively (Scheme 1) [10]. Reaction of 6 
with the lithium salt of 1-tetradecyne gave the 
disilylated TAC 7 with 89 % yield. Ultimate 
proto-desilylation of 7 to the TAC target 4 in the 
presence of K2CO3 in methanol proceeded with 
a 63 % yield. Both the lipidic TACs 7 and 4 
happen to be solid products, which were 































Scheme 1. Four-step synthesis of the mono-lipidic TAC 4. 
  
For the sake of comparison, a TAC bearing a 
single terminal ethynyl moiety and two lipidic 
alkynyl chains was also envisaged. The so-
defined target 8 was prepared in four steps from 
1-tetradecyne, sequentially via the DAC 9 (65 
% yield), the corresponding diynone 10 (70 % 
yield) and the silylated TAC 11 (64 % yield). 
Treatment of the latter with K2CO3 in methanol 
afforded the TAC 8 with 80 % yield. These 
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diynes" [11] or triynes were obtained as solid 
products and characterized by 1H, 13C NMR 
spectroscopy and DCI/CH4 HRMS. 
 
 
Scheme 2. Four-step synthesis of the bis-lipidic TAC 8. 
 
 The cytotoxicity of the TACs 4 and 8 
was evaluated towards the HCT116 cell-line 
(Table 1), and compared with that of the parent 
DAC (S)-(+)-1 (Table 1). Whereas the doubly 
lipidic TAC 8 was found to have no detectable 
activity (IC50 > 120 µM), the mono-lipidic 
counterpart 4 turned out to display a sizeable 
cytotoxicity, with IC50 = 40 µM, namely of the 
same order of magnitude as the BAC rac-2 (10 
µM) (Figure 1). With the particular batch of 
HCT116 cells used for the MTT tests, the 
reference DAC (+)-1 showed a reproducible 
IC50 value of 0.10 µM [5]. 
In the HC≡C–CR'(OH)–C≡CC12H25 tertiary 
series (R' ≠ H), the decrease in cytotoxicity of 
the TACs 4 and 8 (R' = C≡CH, C≡CC12H25) 
with respect to the secondary DAC 1 (R' = H) is 
a priori consistent with a previous observation 
of complete inactivity of the methylated tertiary 
DAC (R' = CH3: IC50 > 50 µM) [9d]. 
Nevertheless, the residual activity of 4 shows 
that the tertiary character of the carbinol center 
is not a crippling criterion. By comparison to the 
tertiary methylated DAC [9d] and TAC 8, the 
sizeable cytotoxicity of 4 gives formal support 
to the ethynylogation approach: from R' = H in 
1 to R' = C≡CH in 4, the structure just 
undergoes a second-order geometrical 
modification, i.e. a translation of the H atom 
from the carbinol center by 2.3 Å, resulting in a 
secondary change of the IC50 value. The same 
translation of another H atom of 1 (the 
acetylenic H) was observed to have the same 
effect (in terms of log units) by going from the 
DAC 1 to the BAC 2 [5].  
 
Table 1. MTT test results against the HCT116 cancer 
cell-line 
Derivative IC50 [nM] 
(S)-(+)-1 0.10 
4 40  
8 > 120  
 
The cytotoxicity was evaluated for the lipidic TACs 4 and 
8 vs their parent lipidic DAC 1. Cells were seeded in 96-
well plates and treated with concentrations ranging from 5 
nM to 120 µM; after 72 h, the number of live cells was 
evaluated by standard MTT tests. MTT test of the three 
compounds were performed in strictly identical conditions 
(in parallel the same days, with the same biological and 
auxiliary chemical materials).  
 
The disclosed results are a priori consistent with a 
basic principle of quantitative SAR (QSAR) 
analysis, stating that continuous variations of a 
single structural parameter (here a C…H distance, 
independently from angular parameters and local 
steric hindrance) entails a "proportional" variation of 
the biological activity at stake [12]. 
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Conclusions and perspectives 
With the view to testing further possible merits 
of the formal ethynylogation approach, the 
present results complete the scope of SARs 
between DACs and anticancer cytotoxicity: 
beyond the formerly explored BAC series [5], 
the TAC series is now addressed, providing the 
first example a tertiary DAC, 4, with a non-
vanishing cytotoxicity. Beyond further 
ethynylogation of the BAC lead 3, further 
prospects are also naturally suggested within the 
generalized DAC series H–C≡C–CR'(OH)–
C≡C–R, and in particular the systematic 
variation of the length of the aliphatic chain R, 
and the C-H fluorination of the carbinol center 
of 1 by going from R' = H to R' = F. The F 
atom should indeed bring less conformational 
disorder than any alkyl or alkylethynyl R' 
group, and ca. a half iso-directional hindrance 
compared to the second ethynyl group of 4 (R' 
= C≡CH). Beside the limited steric effect, an 
additional effect of the F substituent should be 
the enhancement of the OH acidic character. 
 
Experimental part 
Synthesis material and methods 
The reactions were carried out under an argon 
atmosphere, in solvents previously dried and 
distilled: tetrahydrofuran (THF) over sodium/ 
benzophenone, dichloromethane (DCM) over 
CaH2 and methanol (MeOH) over magnesium 
and iodine. All the other solvents, petroleum 
ether (PE), ethyl acetate, and reagents were used 
as commercially available. Commercial 
solutions of n-BuLi were 1.6 M in hexanes. 
Analytic thin-layer chromatography (TLC) was 
performed with 0.20 mm silica gel 60F254 
plates. Chromatograms were revealed under UV 
light and/or moistened with 10 % 
phosphomolybdic acid in EtOH, and visualized 
on a heating plate. Column chromatography was 
carried out on silica gel 60A (SDS 35-70 mm). 
NMR spectra were recorded with a Bruker 
Avance 300 instrument from solutions of the 
samples in CDCl3. 1H and 13C NMR chemical 
shifts δ are quoted in parts per million (ppm), 
with positive values to high frequency relative to 
the tetramethylsilane reference determined from 
the residual or main solvent peak; coupling 
constants J are given in Hertz. Mass spectra (MS) 




To a flame-dried flask equipped with a 
condenser, charged with a solution of 
trimethylsilylacetylene (0.5 mL, 3.61 mmol, 1 
equiv.) in THF (20 mL), was dropwise added 
1.6 M solution of n-BuLi in hexanes (2.2 mL, 
3.43 mmol, 0.95 equiv.) at 0°C. After stirring 
for 20 min at 0 °C, methyl formate (106 mL, 
1.73 mmol, 0.48 equiv.) was added, and the 
resulting solution was gently heated to the limit 
of reflux with the aid of a hair dryer (until 
appearance of small bubbles and colour change 
from yellow to brown). After cooling back to 
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room temperature and treatment with saturated 
aqueous NH4Cl, the aqueous layer was extracted 
with Et2O and the combined organic layers were 
washed with brine, dried over MgSO4, and 
concentrated under reduced pressure. The crude 
product was purified by silica gel 
chromatography (PE/Et2O, 7/3, Rf = 0.7) to give 
369 mg of a solid yellow product assigned to the 
known DAC 5, with 84 % yield. 1H NMR (300 
MHz, CDCl3) δ 5.13 (d, J = 6.6 Hz, 1H), 2.37 
(s, 1H), 0.22 (s, 18H); 13C NMR (75 MHz, 
CDCl3) δ (2 C≡C) 101.65, (2 ≡C-Si) 89.73, (C-
OH) 53.04, (9 C-Si) -0.34. 
 
1,5-bis(trimethylsilyl)penta-1,4-diyn-3-one (6). 
To a solution of 1,5-bis(trimethylsilyl)penta-
1,4-diyn-3-ol 5 (310 mg, 1.38 mmol, 1 equiv.) 
in DCM (15 mL), was added γ-MnO2 in one 
portion (1.8 g, 0.02 mol, 15 equiv.), and the 
mixture was stirred for 24 h at room 
temperature (completion of the reaction 
monitored by TLC). The reaction mixture was 
then filtered through a pad of Celite®, and the 
filtrate was concentrated under reduced 
pressure. The crude product was purified by 
silica gel chromatography (PE/Et2O, 90/10, Rf = 
0.7) to give an orange solid product assigned to 
the known diynone 6 with 82 % yield. 1H NMR 
(300 MHz, CDCl3) δ 0.29 (s, 9H); 13C NMR (75 
MHz, CDCl3) δ (C=O) 160.29, (2 C≡C) 102.51, 
(2 ≡C-Si) 99.41, (9 C-Si) -0.90, -0.92; MS 
(DCI-CH4): m/z (%) [MH+] = 223 (100), 
[MC2H5+] = 251(55). 
1-(trimethylsilyl)-3-[2-(trimethylsilyl)ethynyl] 
heptadeca-1,4-diyn-3-ol (7). A flame-dried 
flask was charged under dry argon with a 
solution of 1-tetradecyne (200 L, 0.81 mmol, 1 
equiv.) in THF (5 mL). To the stirred solution at 
0 °C, was slowly added a 1.6 M solution of n-
BuLi in hexanes (490 L, 0.77 mmol, 0.95 
equiv.). After stirring for 30 min at the same 
temperature, a solution of 1,5-
bis(trimethylsilyl)penta-1,4-diyn-3-one 6 (162 
mg, 0.73 mmol, 0.9 equiv.) in THF (1 mL) was 
added and the mixture was stirred at -78°C for a 
further 10 min. After treatment with saturated 
aqueous NH4Cl solution, the aqueous layer was 
extracted with DCM. The combined organic 
layers were washed with brine, dried over 
MgSO4 and concentrated under reduced 
pressure. The crude product was purified by 
silica gel chromatography (petroleum 
ether/ethyl acetate, 90/10, Rf = 0.15) to give 209 
mg of an orange oil assigned to 7 with 69 % 
yield. 1H NMR (300 MHz, CDCl3) δ 2.80 (s, 
1H), 2.28 (t, J = 7.1 Hz, 2H), 1.63–1.53 (m, 
2H), 1.30 (s, 18H), 0.97–0.85 (m, 3H), 0.24 (s, 
19H). 13C NMR (75 MHz, CDCl3) δ (2 C≡C) 
102.15, (C≡C) 87.35, (2 C≡C) 84.60, (2 C≡C) 
78.11, (C-OH) 54.67, (11 CH2) 31.94, 29.70, 
29.67, 29.65, 29.59, 29.38, 29.17, 28.87, 28.05, 
22.72, 18.78, (CH3) 14.15, (3 C-Si) -0.43; MS 
(DCI-CH4): m/z [MH+] = 417; HRMS (DCI-
CH4): m/z [MH+] calcd = 417.3009, found = 
417.3008. 
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3-ethynylheptadeca-1,4-diyn-3-ol (4). To a 
solution of the silylated TAC 7 (109 mg, 0.261 
mmol, 1equiv.) in methanol (4 mL) was added 
K2CO3 (36 mg, 0.261 mmol, 1 equiv.). The 
solution was stirred for 4 h at room temperature 
(completion of the reaction followed on TLC), 
before treatment with brine. The aqueous layer 
was extracted with DCM, and the combined 
organic layers were dried over MgSO4 and 
concentrated under reduced pressure. The crude 
product was purified by silica gel 
chromatography (PE/Et2O, 90/10, Rf = 0.2) to 
give 44 mg of a clear viscous oil product, 
assigned to 4 with 63 % yield; 1H NMR (300 
MHz, CDCl3) δ 2.93 (s, 1H), 2.71 (s, 2H), 2.29 
(t, J = 7.2 Hz, 2H), 1.64–1.52 (m, 2H), 1.47–
1.23 (m, 18H), 0.90 (t, J = 6.75 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ (C≡C) 85.31, (C≡C) 
81.38, (C≡C) 77.30, (C≡C) 71.00, (C-OH) 
53.83, (11 CH2) 31.94, 29.68, 29.66, 29.62, 
29.50, 29.38, 29.09, 28.87, 28.01, 22.72, 18.66, 
(CH3) 14.15; MS (DCI-CH4): m/z [MH+] = 273; 
HRMS(DCI-CH4): m/z [MH+] calcd = 
273.2218, found = 273.2216. 
 
Nonacosa-13,16-diyn-15-ol (9). A flame-dried 
flask was charged with a solution of 1-
tetradecyne (500 L, 2.03 mmol, 1 equiv.) in 
THF (15 mL), under dry argon atmosphere. A 
1.6 M solution of n-BuLi in hexanes (1.32 mL, 
2.24 mmol, 1.1 equiv.) was added slowly at 0 
°C. The solution was stirred for 30 min at the 
same temperature, then a solution of methyl 
formate (62 μL, 1.02 mmol, 0.5 equiv.) in THF 
(3 mL) was added and the mixture was stirred at 
0°C for further 30 min. After treatment with a 
saturated aqueous NH4Cl solution and 
extractions with DCM, the combined organic 
layers were washed with brine, dried over 
MgSO4 and concentrated under reduced 
pressure. The crude product was purified by 
silica gel chromatography (PE/ethyl acetate, 
95/05, Rf = 0.25) to give 275 mg of a white solid 
product, assigned to 9 with 65 % yield. Mp = 
47°C; 1H NMR (300 MHz, CDCl3) δ 5.1(s, 1H), 
2.25 (td, J = 7.1, 2.1 Hz, 4H), 2.13 (s, 1H), 1.55 
(q, 4H), 1.42–1.30 (m, 36H), 0.92 (t, J = 6.75 
Hz, 6H); 13C NMR (75 MHz, CDCl3) δ (2 C≡C) 
85.23, (2 C≡C) 78.05, (CH-OH) 52.61, (22 
CH2) 31.95, 29.70, 29.67, 29.66, 29.55, 29.39, 
29.16, 28.92, 28.41, 22.72, 18.75 (2 CH3) 14.16, 
14.14; MS (DCI-CH4): m/z [MH+] = 417, 
[MC2H5+] = 445. 
 
Nonacosa-13,16-diyn-15-one (10). To a 
solution of nonacosa-13,16-diyn-15-ol 9 (104 
mg, 0.25 mmol, 1 equiv.) in DCM (10 mL), was 
added γ-MnO2 (326 mg, 3.75 mmol, 15 equiv.) 
in one portion. The mixture was stirred for 24 h 
at room temperature (completion of the reaction 
monitored by TLC). The mixture was then 
filtered through a pad of Celite® using DCM 
and the filtrate was concentrated under reduced 
pressure. The crude product was purified by 
silica gel chromatography (PE/Et2O, 85/15, Rf = 
0.5) to give 72 mg of a white viscous oil 
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product, assigned to 10 with 70 % yield. 1H 
NMR (300 MHz, CDCl3) δ 2.40 (t, J = 7.1 Hz, 
4H), 1.67–1.55 (m, 4H), 1.29 (d, J = 4.9 Hz, 
36H), 0.94–0.85 (m, 6H); 13C NMR (75 MHz, 
CDCl3) δ (C=O) 161.50, (2 C≡C) 94.78, (2 
C≡C) 82.34, (22 CH2) 31.94, 29.67, 29.65, 
29.62, 29.46, 29.38, 29.05, 28.90, 27.58, 22.72, 
19.13, (2CH3) 14.14; IR (neat):  (cm-1) = 3440, 
2965, 2158, 1622, 1255, 1249, 1163, 879, 846, 
760; MS (DCI-CH4): m/z (%) [MH+] = 415 
(100); HRMS (DCI-CH4): m/z [MH+] calcd = 
415.3940, found = 415.3925.  
 
15-[2-(trimethylsilyl)ethynyl]nonacosa-13,16-
diyn-15-ol (11). A flame-dried flask was 
charged with a solution of ethynyl-
trimethylsilane (80 μL, 0.54 mmol, 1.5 equiv) in 
THF (5 mL) under dry argon atmosphere. A 1.6 
M solution of n-BuLi in hexanes (340 L, 0.54 
mmol, 1.5 equiv.) was slowly added at -78 °C. 
After stirring for 30 min at the same 
temperature, a solution of nonacosa-13,16-diyn-
15-one 10 (150 mg, 0.36 mmol, 1 equiv.) in 
THF (0.5 mL) was added and the mixture stirred 
at -78 °C for a further 10 min. After treatment 
with 5 % aqueous NH4Cl solution and 
extractions with DCM, the combined organic 
layers were washed with brine, dried over 
MgSO4 and concentrated under reduced 
pressure. The crude product was purified by 
silica gel chromatography (PE/ethyl acetate, 
90/10, Rf = 0.15) to give 119 mg a yellow 
viscous oil product, assigned to 11 with 64 % 
yield. 1H NMR (300 MHz, CDCl3) δ 2.77 (s, 
1H), 2.27 (t, J = 7.2 Hz, 4H), 1.60-1.55 (m, 4H), 
1.47–1.22 (m, 36H), 0.91 (t, J = 6.4, 1.9 Hz, 
6H), 0.23 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 
(C≡C) 102.82, (C≡C) 86.55, (C≡C) 83.96, 
(C≡C) 78.69, (C-OH) 54.56, (22 CH2) 31.95, 
29.71, 29.67, 29.67, 29.58, 29.39, 29.17, 28.89, 
28.14, 22.72, 18.77, (2 CH3) 14.16, 14.14, (3 C-
Si) -0.36; MS (DCI-CH4): m/z [MH+] = 513; 
HRMS (DCI-CH4): m/z [MH+] calcd = 
513.4492, found = 513.4481. 
 
15-ethynylnonacosa-13,16- diyn-15-ol (8). To 
a solution of the silylated trialkynylcarbinol 11 
(80 mg, 0.16 mmol, 1 equiv) in methanol (2 
mL) was added K2CO3 (20 mg, 0.16 mmol, 1 
equiv.). The solution was stirred for 4 h at room 
temperature (completion of the reaction 
followed on TLC) before treatment with brine. 
The aqueous layer was extracted with DCM, 
and the combined organic layers were dried 
over MgSO4 and concentrated under reduced 
pressure. The crude product was purified by 
silica gel chromatography (PE/Et2O, 85/15, Rf = 
0.15) to give 55 mg of a white viscous oil 
product, assigned to 8 with 80 % yield. 1H NMR 
(300 MHz, CDCl3) δ 2.77 (s, 1H), 2.66 (s, 1H), 
2.28 (t, J = 7.2 Hz, 4H), 1.66–1.50 (m, 4H), 
1.50–1.21 (m, 36H), 0.97–0.84 (m, 6H).13C 
NMR (75 MHz, CDCl3) δ (C≡C) 84.29, (C≡C) 
82.38, (C≡C) 78.29, (C≡C) 70.09, (C-OH) 
54.16, (22 CH2) 31.95, 29.71, 29.68, 29.65, 
29.54, 29.39, 29.13, 28.90, 28.12, 22.72, 18.71, 
FRENCH-UKRAINIAN JOURNAL OF CHEMISTRY (2017, VOLUME 05, ISSUE 01)  
32 
 
(2 CH3) 14.15; MS (DCI-CH4): m/z [MH+] = 
441, [MC2H5+] = 469; HRMS (DCI-CH4): m/z 
[MH+] calcd = 441.4096, found = 441.4091. 
 
Biological evaluations 
 MTT tests (MTT = (3-[4,5-diMethylThiazol-2-
yl]-2,5-diphenyl Tetrazolium bromide). The 
drugs' cytotoxicity was determined by standard 
MTT tests on HCT116 cells. In brief, 10.000 
HCT116 cells were distributed in 96 flat bottom 
well plates in 100 microliters of DMEM 10 % 
FCS and 1 µL of DMSO containing the drugs 
dilutions were then added to each well. For each 
drug, triplicates of concentrations ranging from 
10 M to 5 nM were carried out, by means of 7 
successive three fold dilutions of a 1 mM stock 
solution. Controls always included medium 
alone, DMSO alone and dilutions of the 
reference drug (S)-(+)-1 (IC50 around 0.1 µM). 
Plates were then placed in a CO2 tissue culture 
incubator for 72 h before the MTT test was 
performed. This was done by adding 10 µL of 
MTT stock solution (12 M, 5 mg/mL in PBS, 
Sigma) to each well and incubating the plate for 
90 min at 37°C. 100 L of a 0.1 M HCl aqueous 
solution in isopropanol (v/v 1/9) were then 
added to each well, and the plates were returned 
to 37°C for 90 min before reading the OD 
absorbed at 570 nm.  
Supporting Information. 1H and 13C NMR 
spectra of the eight compounds 4-11. 
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